These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36471131)

  • 1. How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe.
    Avşar TS; Yang X; Lorgelly P
    Pharmacoeconomics; 2023 Feb; 41(2):123-138. PubMed ID: 36471131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equity in national healthcare economic evaluation guidelines: Essential or extraneous?
    Saygın Avşar T; Yang X; Lorgelly P
    Soc Sci Med; 2024 Sep; 357():117220. PubMed ID: 39153234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation of Medically Assisted Reproduction: A Methodological Systematic Review.
    Van Muylder A; D'Hooghe T; Luyten J
    Med Decis Making; 2023; 43(7-8):973-991. PubMed ID: 37621143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.
    Khorasani E; Davari M; Kebriaeezadeh A; Fatemi F; Akbari Sari A; Varahrami V
    Eur J Health Econ; 2022 Dec; 23(9):1577-1590. PubMed ID: 35235078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of HTA guidelines on societal and novel value elements.
    Breslau RM; Cohen JT; Diaz J; Malcolm B; Neumann PJ
    Int J Technol Assess Health Care; 2023 May; 39(1):e31. PubMed ID: 37226807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
    Mathes T; Jacobs E; Morfeld JC; Pieper D
    BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review.
    Farah L; Davaze-Schneider J; Martin T; Nguyen P; Borget I; Martelli N
    Artif Intell Med; 2023 Jun; 140():102547. PubMed ID: 37210155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluations in fracture research an introduction with examples of foot fractures.
    van den Boom N; van den Hurk AA; Kalmet P; Poeze M; Evers S
    Injury; 2022 Mar; 53(3):895-903. PubMed ID: 35034777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding health technology assessment towards broader value: Ireland as a case study.
    Kinchin I; Walshe V; Normand C; Coast J; Elliott R; Kroll T; Kinghorn P; Thompson A; Viney R; Currow D; O'Mahony JF
    Int J Technol Assess Health Care; 2023 May; 39(1):e26. PubMed ID: 37129030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries.
    Zisis K; Naoum P; Athanasakis K
    Int J Technol Assess Health Care; 2020 Dec; 37():e2. PubMed ID: 33298238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations.
    Hoxhaj I; Castagna C; Calabrò GE; Boccia S
    Front Public Health; 2022; 10():795763. PubMed ID: 35223734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report.
    Drummond MF; Augustovski F; Bhattacharyya D; Campbell J; Chaiyakunapruk N; Chen Y; Galindo-Suarez RM; Guerino J; Mejía A; Mujoomdar M; Ollendorf D; Ronquest N; Torbica A; Tsiao E; Watkins J; Yeung K;
    Value Health; 2022 Aug; 25(8):1257-1267. PubMed ID: 35931428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.